Source:http://linkedlifedata.com/resource/pubmed/id/10631467
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
11
|
pubmed:dateCreated |
2000-2-10
|
pubmed:abstractText |
We present the case of a patient with a locally advanced hypopharyngeal carcinoma who developed a severe cytomegalovirus (CMV) colitis after his first chemotherapy course with 5-fluorouracil (5-FU), docetaxel and cisplatin. The most probable cause of his CMV colitis is the impaired immunity during a phase of neutropenia after the chemotherapy. Although there was amelioration of the colitis and clinical status after treatment with ganciclovir, the patient later deteriorated and died due to recurrent bacterial infections. This is the third reported case of CMV colitis treated with ganciclovir in a patient with a solid tumour. It is the first report of CMV colitis after docetaxel containing chemotherapy. Although CMV colitis is most frequently observed in immunosuppressed patients such as those with acquired immune deficiency syndrome (AIDS), transplants and corticosteroid treatment, it has also been reported in less immunosuppressed (elderly, malnourished,...) and even non-immunosuppressed patients. CMV infection should therefore be included in the differential diagnosis of GI disease in all patients, and when suspected, the clinician should pursue appropriate diagnostic and therapeutic interventions.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil,
http://linkedlifedata.com/resource/pubmed/chemical/Ganciclovir,
http://linkedlifedata.com/resource/pubmed/chemical/Paclitaxel,
http://linkedlifedata.com/resource/pubmed/chemical/Taxoids,
http://linkedlifedata.com/resource/pubmed/chemical/docetaxel
|
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
0923-7534
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
10
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1369-72
|
pubmed:dateRevised |
2006-4-24
|
pubmed:meshHeading |
pubmed-meshheading:10631467-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10631467-Carcinoma, Squamous Cell,
pubmed-meshheading:10631467-Cisplatin,
pubmed-meshheading:10631467-Colitis,
pubmed-meshheading:10631467-Cytomegalovirus Infections,
pubmed-meshheading:10631467-Fatal Outcome,
pubmed-meshheading:10631467-Fluorouracil,
pubmed-meshheading:10631467-Ganciclovir,
pubmed-meshheading:10631467-Humans,
pubmed-meshheading:10631467-Hypopharyngeal Neoplasms,
pubmed-meshheading:10631467-Immune Tolerance,
pubmed-meshheading:10631467-Male,
pubmed-meshheading:10631467-Middle Aged,
pubmed-meshheading:10631467-Paclitaxel,
pubmed-meshheading:10631467-Taxoids
|
pubmed:year |
1999
|
pubmed:articleTitle |
Cytomegalovirus colitis after administration of docetaxel-5-fluorouracil-cisplatin chemotherapy for locally advanced hypopharyngeal cancer.
|
pubmed:affiliation |
Department of Medical Oncology, University Hospital Antwerp (UZA), Edegem, Belgium. JanVdBra@mail.dma.be
|
pubmed:publicationType |
Journal Article,
Case Reports
|